Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
KOGANEI Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, showing a one-to-one ratio between pending matters and examining staff. The prosecution is further divided across 2 distinct art units, which reflects a breadth of technical subject matter even within the primary technology category. This structure indicates that the company's research output is being evaluated by diverse technical experts at the USPTO.
The busiest examiner, MILLER, DALE R, is currently overseeing 1 pending office action. This represents half of the total pending actions for the company. With 1 busiest examiner pending action, the workload is evenly split among the assigned officials. This distribution suggests that the company's patent prosecution is not bottlenecked by a single examiner, as each official manages an equal portion of the current workload across the 2 art units. Practitioners should prepare for distinct negotiation styles, as the 2 examiners operate in different units, requiring tailored arguments for each specific biological innovation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MILLER, DALE R | 1 | 62.5% | +17.6% |
| LEE, GILBERT Y | 1 | 78.8% | +10.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355979 | Non-Contact Conveyance Device | LEE, GILBERT Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693800 | METHOD FOR PRODUCING CYCLIC OLIGOSACCHARIDE, CYCLIC OLIGOSACCHARIDE AND INCLUSION AGENT | MILLER, DALE R | — |
| 18355979 | Non-Contact Conveyance Device | LEE, GILBERT Y | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 3675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693800 | METHOD FOR PRODUCING CYCLIC OLIGOSACCHARIDE, CYCLIC OLIGOSACCHARIDE AND INCLUSION AGENT | MILLER, DALE R | 1693 | §102 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18355979 | Non-Contact Conveyance Device | LEE, GILBERT Y | 3675 | §102§103 | Non-Final OA | — | Pending | Jul 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKOGANEI Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dale R Miller has the most, with 1 of KOGANEI Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
